See more : Xiamen Leading Optics Co., Ltd. (605118.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Betta Pharmaceuticals Co., Ltd. (300558.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Betta Pharmaceuticals Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- J&T Global Express Ltd (1519.HK) Income Statement Analysis – Financial Results
- ODIMO INC (ODMO) Income Statement Analysis – Financial Results
- Three Valley Copper Corp. (TVC.V) Income Statement Analysis – Financial Results
- vft (6979.TWO) Income Statement Analysis – Financial Results
- Heartland Group Holdings Limited (HGH.NZ) Income Statement Analysis – Financial Results
Betta Pharmaceuticals Co., Ltd. (300558.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bettapharma.com
About Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.46B | 2.38B | 2.25B | 1.87B | 1.55B | 1.22B | 1.03B | 1.04B | 914.66M | 704.44M | 480.70M | 312.38M | 62.83M |
| Cost of Revenue | 404.48M | 268.69M | 174.44M | 138.90M | 105.23M | 68.99M | 43.70M | 32.83M | 27.94M | 24.41M | 21.37M | 21.59M | 10.22M |
| Gross Profit | 2.05B | 2.11B | 2.07B | 1.73B | 1.45B | 1.16B | 982.66M | 1.00B | 886.72M | 680.02M | 459.33M | 290.80M | 52.61M |
| Gross Profit Ratio | 83.53% | 88.69% | 92.23% | 92.57% | 93.23% | 94.36% | 95.74% | 96.83% | 96.94% | 96.53% | 95.55% | 93.09% | 83.73% |
| Research & Development | 640.14M | 699.90M | 565.95M | 362.85M | 326.36M | 303.70M | 202.73M | 161.50M | 119.94M | 88.27M | 65.46M | 39.74M | 0.00 |
| General & Administrative | 133.09M | 316.77M | 192.97M | 135.65M | 138.04M | 99.80M | 73.97M | 27.02M | 25.37M | 21.71M | 11.22M | 58.92M | 21.99M |
| Selling & Marketing | 563.47M | 779.06M | 814.72M | 684.00M | 562.99M | 496.35M | 393.89M | 398.58M | 337.82M | 251.28M | 171.21M | 120.76M | 27.84M |
| SG&A | 1.12B | 1.10B | 1.01B | 819.66M | 701.03M | 596.15M | 467.86M | 425.60M | 363.19M | 272.99M | 182.43M | 179.68M | 49.83M |
| Other Expenses | 20.53M | 103.81M | 116.37M | 106.30M | 109.55M | 1.67M | 69.66M | 58.56M | 40.64M | 17.96M | 17.42M | 17.71M | 18.77M |
| Operating Expenses | 1.78B | 1.90B | 1.69B | 1.29B | 1.14B | 960.87M | 720.10M | 638.67M | 528.36M | 394.09M | 271.78M | 185.52M | 50.58M |
| Cost & Expenses | 2.19B | 2.17B | 1.86B | 1.43B | 1.24B | 1.03B | 763.80M | 671.50M | 556.30M | 418.51M | 293.15M | 207.10M | 60.80M |
| Interest Income | 8.65M | 10.88M | 18.40M | 5.79M | 3.29M | 2.57M | 3.01M | 1.94M | 1.14M | 1.92M | 643.99K | 4.19M | -0.57 |
| Interest Expense | 54.95M | 195.80M | 15.78M | 39.86M | 48.06M | 25.19M | 3.03M | 3.06M | 1.96M | 922.50K | 531.64K | 0.00 | 5.16M |
| Depreciation & Amortization | 303.49M | 253.70M | 174.46M | 155.86M | 143.46M | 99.90M | 68.25M | 20.08M | 17.86M | 16.63M | 14.75M | 5.82M | 3.08M |
| EBITDA | 696.09M | 455.49M | 580.88M | 862.85M | 457.27M | 309.83M | 366.01M | 459.40M | 410.04M | 311.38M | 208.32M | 105.28M | 2.03M |
| EBITDA Ratio | 28.34% | 19.17% | 25.81% | 46.71% | 29.43% | 25.15% | 35.21% | 43.34% | 45.74% | 46.32% | 46.15% | 34.14% | 3.21% |
| Operating Income | 270.07M | 201.78M | 395.60M | 680.67M | 266.56M | 180.71M | 221.00M | 366.37M | 358.11M | 290.56M | 189.29M | 100.83M | -1.06M |
| Operating Income Ratio | 11.00% | 8.49% | 17.61% | 36.39% | 17.15% | 14.76% | 21.53% | 35.40% | 39.15% | 41.25% | 39.38% | 32.28% | -1.69% |
| Total Other Income/Expenses | 52.01M | -114.21M | -5.67M | -14.01M | -107.81K | 1.67M | 69.66M | 58.55M | 40.61M | 18.19M | 17.17M | 12.05M | 18.75M |
| Income Before Tax | 322.07M | 87.57M | 389.93M | 666.66M | 266.46M | 182.37M | 290.66M | 424.46M | 398.72M | 308.34M | 206.46M | 117.33M | 17.68M |
| Income Before Tax Ratio | 13.11% | 3.68% | 17.36% | 35.65% | 17.15% | 14.90% | 28.32% | 41.01% | 43.59% | 43.77% | 42.95% | 37.56% | 28.14% |
| Income Tax Expense | -11.54M | -37.19M | 10.37M | 65.58M | 40.62M | 18.85M | 39.88M | 56.59M | 55.29M | 41.13M | 28.27M | 12.26M | -1.13M |
| Net Income | 348.03M | 145.42M | 383.07M | 606.36M | 230.82M | 166.82M | 257.73M | 368.80M | 345.30M | 269.29M | 178.40M | 104.90M | 17.56M |
| Net Income Ratio | 14.17% | 6.12% | 17.06% | 32.42% | 14.85% | 13.63% | 25.11% | 35.63% | 37.75% | 38.23% | 37.11% | 33.58% | 27.94% |
| EPS | 0.83 | 0.35 | 0.92 | 1.50 | 0.58 | 0.42 | 0.64 | 1.01 | 0.96 | 0.75 | 0.50 | 1.85 | 0.05 |
| EPS Diluted | 0.83 | 0.35 | 0.92 | 1.49 | 0.57 | 0.42 | 0.64 | 1.01 | 0.96 | 0.75 | 0.50 | 1.85 | 0.05 |
| Weighted Avg Shares Out | 419.32M | 415.49M | 415.39M | 404.24M | 401.00M | 397.19M | 401.00M | 365.14M | 359.69M | 359.05M | 356.80M | 356.80M | 356.80M |
| Weighted Avg Shares Out (Dil) | 419.32M | 415.49M | 415.39M | 406.95M | 404.95M | 397.19M | 402.70M | 365.14M | 359.69M | 359.05M | 356.80M | 356.80M | 356.80M |
Source: https://incomestatements.info
Category: Stock Reports